X
More than 60,000 patients use Brite
4.6 stars
Your health finally understandable with Brite
1
Enter email and you're done. No subscription, no credit card.
2
Search, tap and you're done. Over 3,400 medicines.
3
Check, remind, get an overview.
Sarah K., 34
I finally understand my therapy. The app reminds me, answers my questions — and I don't feel alone with it anymore.
Valsartan is one of the most used blood-pressure lowerers in Germany and belongs to the group of the sartans (angiotensin II receptor blockers). About 30 million people in Germany have high blood pressure (a German figure, broadly comparable across Western countries), many of them treated with sartans. Unlike ACE inhibitors such as ramipril, valsartan as a rule causes no dry cough — but potassium and kidney values have to be checked regularly.
See more detail.gif)
Valsartan is contraindicated in pregnancy - harm to the child is possible. Potassium and kidney values are checked regularly. With angioedema (facial swelling with breathlessness), call the emergency services immediately (112; or 999/112 in the UK). Last updated: May 2026.
Valsartan is one of the most widely used blood-pressure-lowering medicines and the most important representative of the sartan group. Below are the key facts for quick orientation; the individual points are explained in detail in the following chapters.
| Property | Details |
|---|---|
| Active substance | Valsartan - angiotensin II receptor blocker (sartan/ARB) |
| Trade names | Diovan, valsartan generics; combination products Exforge (with amlodipine), Co-Diovan (with HCT) |
| ATC code | C09CA03 - angiotensin II receptor antagonists |
| Mechanism of action | Blockade of the AT1 receptors - angiotensin II can no longer narrow the vessels; blood pressure falls, aldosterone release reduced |
| Main indications | High blood pressure, heart failure, after a heart attack, kidney protection in diabetes |
| Usual dose | 80-320 mg/day, once daily |
| Onset of action | First reduction in days, full effect after 2-4 weeks |
| Important advantage over ACE inhibitors | No dry irritant cough |
| Important checks | Potassium and kidney values before the start and over the course |
| Strictly contraindicated | Pregnancy (harm to the child); combination with ACE inhibitors |
| Prescription status | Yes |
Valsartan is a frequently prescribed medicine for lowering blood pressure and for treating heart failure. It belongs to the group of sartans (also called angiotensin II receptor blockers or ARBs). It is known under the trade name Diovan; there are numerous generics and combination products. Valsartan is one of the most widely used blood-pressure medicines of all.
Sartans like valsartan are, alongside the ACE inhibitors, calcium channel blockers (e.g. amlodipine) and diuretics (water tablets), one of the four most important pillars of high-blood-pressure therapy. An important advantage of valsartan over the ACE inhibitors: it as a rule causes no dry irritant cough - a common and bothersome side effect of the ACE inhibitors.
Valsartan is usually well tolerated, but requires attention to a few points: the monitoring of potassium and kidney values, the strict contraindication in pregnancy and the fact that high blood pressure requires long-term therapy. We explain these topics in detail.
Valsartan intervenes in the renin-angiotensin-aldosterone system (RAAS) - a central hormone system for the regulation of blood pressure and fluid balance. The decisive actor is the hormone angiotensin II, which strongly narrows the blood vessels and thereby raises the blood pressure. In addition, it promotes the release of aldosterone, which retains water and salt in the body.
Valsartan blocks the receptors on which angiotensin II acts (the AT1 receptors). As a result, the hormone cannot develop its vessel-narrowing effect - the vessels relax and widen, the blood pressure falls. At the same time, less aldosterone is released, which reduces the retention of water and salt.
Valsartan is absorbed after oral intake and excreted predominantly via the bile/gut (less via the kidneys than some other sartans). The effect lasts a long time, so that the once-daily intake is sufficient. The blood-pressure-lowering effect builds up over about 2 to 4 weeks - the full effect does not show immediately, but after a few weeks.
A practically very important point. Sartans (like valsartan) and ACE inhibitors (like ramipril, enalapril) both intervene in the same hormone system (RAAS) and lower the blood pressure with similar effectiveness. The decisive difference lies in the side-effect profile:
| Aspect | Sartans (valsartan) | ACE inhibitors (ramipril) |
|---|---|---|
| Mechanism of action | Blockade of the AT1 receptor | Inhibition of angiotensin formation |
| Blood-pressure lowering | Comparably good | Comparably good |
| Heart/kidney protection | Comparably good | Comparably good |
| Dry irritant cough | As a rule not | Common (in a relevant proportion) |
| Angioedema (swelling) | Very rare | Rare, but more common than sartans |
| Potassium rise | Possible | Possible (similar) |
| Combination possible? | NO - no combination with an ACE inhibitor | NO - no combination with sartans |
Sartans are therefore often used when ACE inhibitors are not tolerated because of the cough - or from the outset, when this advantage is wanted. Important: sartans and ACE inhibitors are not combined with each other (no additional benefit, more side effects). The choice is made by the doctor.
The main indication. In high blood pressure, valsartan lowers the blood pressure and thereby reduces, in the long term, the risk of secondary diseases such as heart attack, stroke, heart failure and kidney damage. It is used alone or in combination with other blood-pressure medicines.
In heart failure, valsartan improves the prognosis and symptoms - it relieves the heart by widening the vessels and reducing the fluid load. It is an established building block of heart-failure therapy.
After a heart attack with impaired heart function, valsartan can be used to improve the prognosis.
In certain kidney diseases (especially in diabetes with beginning kidney damage), sartans can protect the kidneys and slow the progression - by lowering the pressure in the kidney vessels.
High blood pressure can often be treated better with a combination of several substances at a lower dose than with a single one at a high dose - this improves the effect and reduces side effects. Valsartan is therefore available in fixed combination products:
The advantage of fixed combination products: fewer tablets, better adherence to therapy. The selection is guided by the blood pressure, accompanying diseases and tolerability. The individual components each have their own side-effect profiles, which the doctor takes into account.
Unlike some other blood-pressure medicines, valsartan usually does not have to be strictly tapered on stopping - nevertheless, stopping should always be discussed with the doctor, as the blood pressure otherwise rises again.
Valsartan is usually well tolerated - sartans are among the best-tolerated blood-pressure medicines. Possible side effects:
An important advantage: unlike ACE inhibitors, valsartan as a rule causes no dry irritant cough. Most side effects are mild and occur mainly at the start. With strong dizziness (especially on standing up), the dose should be reviewed.
An important safety topic with all RAAS inhibitors (sartans and ACE inhibitors). Since valsartan intervenes in the hormone system that also regulates the potassium and fluid balance as well as the blood flow to the kidneys, regular checks are important:
Valsartan can raise the potassium level in the blood (hyperkalaemia). Too high a potassium value can cause dangerous cardiac arrhythmias. The risk rises with impaired kidney function, with combination with other potassium-raising agents (certain diuretics, potassium preparations, salt substitutes with potassium) and with diabetes.
Valsartan influences the blood flow to the kidneys. In most patients this is unproblematic or even kidney-protective; in certain situations (e.g. renal artery narrowing, fluid deficiency), however, the kidney function can worsen. That is why the kidney values are monitored.
Women of childbearing age should know this and speak with the doctor early when wishing to have children - a timely switch to an agent compatible with pregnancy is important. Valsartan is also as a rule not recommended during breastfeeding; here there are more suitable alternatives. This point is mentioned here as important safety information - the individual advice is given by a doctor.
| Substance/category | Effect | Recommendation |
|---|---|---|
| Potassium-sparing diuretics (spironolactone, amiloride), potassium preparations, salt substitutes with potassium | Increased hyperkalaemia risk | Caution, potassium checks |
| ACE inhibitors | More side effects, no additional benefit | Avoid the combination |
| NSAIDs (ibuprofen, diclofenac and others) | Weaken the blood-pressure-lowering effect; "triple whammy" with diuretics | Avoid, better paracetamol |
| Lithium | Increased lithium levels possible | Level checks |
| Other blood-pressure-lowering agents, diuretics | Enhanced blood-pressure lowering (often wanted) | Watch the blood pressure |
| Certain diabetes medicines | Blood-sugar and potassium changes | Caution, monitoring |
The combination with potassium-raising agents and with NSAIDs in particular is relevant. Before any new medication (including over-the-counter painkillers), consult a doctor/pharmacist. More under Interactions of medicines and Taking medicines correctly.
On the topic of alcohol, there are a few things to bear in mind with valsartan:
Practical recommendation: moderate alcohol consumption is usually possible, but with high blood pressure restraint is generally sensible - because regular alcohol raises the blood pressure. Watch out for enhanced dizziness after alcohol. With high blood pressure, a moderate approach to alcohol is part of the healthy lifestyle that supports the therapy.
Since valsartan is usually taken permanently against high blood pressure, a basic understanding of blood pressure and self-measurement helps:
Regular blood-pressure self-measurement is a valuable tool for therapy monitoring. Important: high blood pressure is treated to prevent secondary damage (heart attack, stroke, kidney/heart damage) - even if one feels healthy.
| Observation | Frequency | Typical comment |
|---|---|---|
| Switch from ramipril to valsartan because of a dry cough | Very common | "After 2 years with ramipril and a constant cough - the switch to valsartan took the cough away within 2 weeks." |
| Self-directed stopping with "good" values | Common | "I thought I no longer needed the medicine - 4 weeks later the blood pressure was back at 170." |
| NSAID self-medication - blood pressure rises | Very common | "Ibuprofen daily for knee pain - then the blood pressure was suddenly bad again, my GP recognised the connection." |
| Dizziness on standing up especially in the morning | Common | "At the start, everything went black on standing up in the morning - with standing up slowly and a sitting pause it improved after 2 weeks." |
| Hyperkalaemia with a spironolactone combination | Common | "With valsartan and spironolactone together, the potassium was at 5.8 - now only valsartan, the potassium is normal." |
| Pregnancy - switch to methyldopa | Rare but important | "With a wish to have children I had to stop valsartan - my gynaecologist switched to alpha-methyldopa, which is permitted in pregnancy." |
Valsartan experiences after a switch from ramipril - is it worth it? With a dry cough under an ACE inhibitor, almost always a clear yes. The dry irritant cough occurs in about 5-20% of ACE-inhibitor users and is one of the most common causes of discontinuation of therapy. What to expect: after the switch, the cough usually disappears within 1-4 weeks (sometimes longer), the blood-pressure control remains comparably good. Important: ACE inhibitors and sartans are not equivalent in every respect - in some high-risk constellations (e.g. after a heart attack with impaired pumping function) there are more study data for ACE inhibitors, but sartans are a very good alternative. Practically: those who cannot bear the cough should raise it - quality of life and adherence rise with a well-tolerated medicine.
The valsartan scandal of 2018 - what happened? An important episode in pharmaceutical legislation. In 2018, in valsartan generics of certain manufacturers (especially from China and India), carcinogenic impurities (NDMA and NDEA) were detected - arising during synthesis. The EMA and BfArM (Germany) ordered extensive recalls. What patients need to know: the production processes have since been revised, tests are strict, newer batches are controlled. The absolute risk from the short-term exposure was assessed as low. Practically today: pharmacists check the batches, the generics produced after 2018 are considered safe. With concerns, alternative sartans (e.g. candesartan, losartan, olmesartan), which were not affected, can be discussed with the doctor.
Valsartan experiences with ankle oedema - does it come from the sartan? Rather not directly - ankle oedema is typical of calcium channel blockers like amlodipine, not of valsartan. But: in the common combination valsartan + amlodipine (Exforge), ankle oedema often occurs through the amlodipine - the sartan even partly alleviates it. If ankle oedema is bothersome: often a reduction of the amlodipine dose with a simultaneous increase of the valsartan helps, a switch to other calcium channel blockers (e.g. lercanidipine, which causes less oedema), or the addition of a diuretic. Important to distinguish: ankle oedema from amlodipine is harmlessly cosmetic, whereas swelling from heart failure or kidney failure is a warning sign - with sudden occurrence or one-sided swelling, have it investigated by a doctor.
Valsartan's effect is wearing off - what to do? Several possible causes. The most common reasons: weight gain (a higher blood-pressure need), increased salt consumption, alcohol, sleep apnoea (very often underdiagnosed!), new pain medication with NSAIDs, an increase in stress, irregularity of intake. Pharmacologically: a genuine weakening of the effect is rare with sartans - rather, a "hidden" problem lies behind it. Diagnostically: a blood-pressure diary over 7-14 days, possibly a 24-hour blood-pressure measurement, an examination for sleep apnoea (snoring, daytime fatigue, overweight), cholesterol and kidney values. Therapeutically: increase the dose (e.g. from 80 to 160 mg), combination with amlodipine or HCT, lifestyle optimisation, treatment of sleep apnoea. Rarely: look for secondary causes of hypertension (e.g. renal artery stenosis, an adrenal tumour).
Valsartan and sex - are there side effects? Compared with other blood-pressure medicines very favourable. While beta blockers and older diuretics frequently cause erectile dysfunction and loss of libido, sartans like valsartan are in this respect neutral or even favourable. Some studies even suggest that sartans can improve sexual function in high-blood-pressure patients - presumably through the lowering of the blood pressure and the improvement of endothelial function. If erectile dysfunction occurs under valsartan: usually look for other causes (diabetes, CHD, overweight, stress, psychological factors), review the medicine combination (beta blockers, diuretics?), a sildenafil combination is usually safely possible. Important: with new erectile dysfunction, have it investigated by a doctor - it can be an early warning sign of cardiovascular disease, not just a medicine side effect.